Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company developing non-opioid medicines for pain. Its programs focus on selectively blocking the Nav1.8 sodium channel, which plays a role in transmitting pain signals in peripheral nerves, with the goal of relieving pain without the addiction risk associated with opioids.

The company's lead candidates are oral small molecules being studied in acute pain and other pain conditions, and it is also exploring additional targets in pain biology. Latigo is based in Southern California, and its common stock trades on the Nasdaq under the ticker LTGO.